Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

Author： Wolowacz Sorrel E.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.10, 2007-01, pp. : 863-879

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

By Moshfeghi Andrew A   Puliafito Carmen A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 671-682

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A.   Keating Gillian M.  

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

Pegaptanib of value for age-related macular degeneration

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration

By Mitchell Paul  

PharmacoEconomics, Vol. 29, Iss. 2, 2011-02 ,pp. : 107-131

Adis International

Access to resources Recommend Favorite

Pegaptanib in exudative age-related macular degeneration: profile report

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 12, 2005-12 ,pp. : 6-8

Adis International

Access to resources Recommend Favorite